U.S. stock movement | BeiGene (ONC.US) rises over 2%: Institutions say Chinese innovative drugs going global are not affected by tariffs.

According to the Securities Times APP, on Monday, BeiGene (ONC.US) rose over 2% to $251.10. CICC International believes that the enthusiasm of multinational corporations (MNC) for acquiring Chinese mainland innovative drug assets remains strong and will continue to be an important driver for the overseas expansion of Chinese mainland innovative drugs. Influenced by factors such as tariffs and geopolitics, as well as the gradual implementation of centralized procurement, the acceleration of domestic substitution will benefit leading domestic equipment manufacturers. In addition, the main way for Chinese mainland innovative drugs to go overseas is through authorized overseas models, which do not involve actual product exports and are not affected by tariffs.